Mandate

VINGE ADVISES INDUSTRIFONDEN IN CONNECTION WITH THE FINANCING OF HASSELBLAD’S NEW CAMERAS

December 11, 2013

Industrifonden has provided financing to the camera maker, Hasselblad, in the form of a loan of approximately SEK 78 million with detachable options. The funds will be used for the launch of Hasselblad’s new series of cameras and for renewal of the existing range of cameras.

The new cameras will be available on the market shortly and the first two models, i.e. Lunar and Stellar, were launched recently. Since they are intended for amateur photographers, they are in a lower price and performance segment compared to Hasselblad’s traditional range of products, which are directed toward professional photographers.

Hasselblad’s current owner, the German-Swiss private equity firm, Vorndran Mannheims Capital, has made significant contributions in the form of renewal and greater degree of frequency of change of models in the existing H-system, where H5D was launched at the beginning of 2013.

Hasselblad’s production and R&D divisions are now based in Gothenburg where the company has doubled its production capacity and has recruited new personnel. Hasselblad is thus once again primarily a Swedish company.

Vinge’s team consisted of partner Johan Larsson and associate Lisa Antman.   

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026